eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Basic research

miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2

Hui-Ning Liu, Peng Qie, Guang Yang, Yong-Bin Song

Arch Med Sci 2018; 14, 4: 745–751
Online publish date: 2018/02/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
MicroRNAs (miRNAs) are a group of small non-coding RNAs that affect multiple aspects of tumor biology including chemo resistance. miR-181b has been reported to modulate multidrug resistance in non-small cell lung cancer cells. This study was undertaken to determine the role of miR-181b in chemo resistance of small cell lung cancer cells.

Material and methods
This study was undertaken to determine the role of miR-181b in chemoresistance of small cell lung cancer cells with use of qRt-PCR, WB, bioinformatics analysis, and double luciferase reporter system.

Results
Our data showed that miR-181b was significantly downregulated in cisplatin-resistant H446 small cell lung cancer cells, compared to parental cells, compared to parental cells. Ectopic expression of miR-181b inhibited cell proliferation and invasion in cisplatin-resistant H446 cells (p = 0.023). Moreover, overexpression of miR-181b increased the susceptibility of cisplatin-resistant H446 cells to cisplatin. Mechanistic investigations demonstrated that miR-181b inhibited B-cell lymphoma-2 (Bcl-2) expression by binding to the 3'-untranslated region. Overexpression of Bcl-2 reversed miR-181b-mediated chemo sensitization, which is accompanied by a reduced apoptotic response.

Conclusions
Taken together, this work demonstrated that miR-181b might have the ability to overcome chemo resistance of small cell lung cancer cells, and restoration of this miRNA may represent a potential therapeutic strategy for improving chemo sensitivity in small cell lung cancer.

keywords:

miR-181b, small cell lung cancer cells, Bcl-2, cisplatin-resistant

references:
Shimasaki N, Inoue K, Nishigawa H, et al. Combined small cell carcinoma and sarcomatoid squamous cell carcinoma in the renal pelvis. Int J Urol 2005; 23: 686-9.
Chang CY, Reddy K, Chorneyko K, et al. Primary small cell carcinoma of the ureter. Canadian J Urol 2005; 12: 2603-6.
Khattar NH, Lele SM, Kaetzel CS. Down-regulation of the polymeric immunoglobulin receptor in non-small cell lung carcinoma: correlation with dysregulated expression of the transcription factors USF and AP2. J Biomed Sci 2005; 12: 65-77.
Nakamura Y, Tajiri T, Uchida E, et al. Changes to levels of serum neuron-specific enolase in a patient with small cell carcinoma of the pancreas. J Hepatobiliary Pancreat Surg 2005; 12: 93-8.
Rebelatto MC, Midha A, Mistry A, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathol 2016; 11: 95.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-74.
Zhu Z, Wang G, Ma K, et al. GABAergic neurons in nucleus accumbens are correlated to resilience and vulnerability to chronic stress for major depression. Oncotarget 2017; 8: 35933-45.
Ma K, Xu A, Cui S, et al. Impaired GABA synthesis, uptake and release are associated with depression-like behaviors induced by chronic mild stress. Transl Psychiatry 2016; 6: e910.
Ma K, Guo L, Xu A, et al. Molecular mechanism for stress-induced depression assessed by sequencing miRNA and mRNA in medial prefrontal cortex. PloS One 2016; 11: e0159093.
Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, et al. Disturbances in apoptosis of lamina propria lymphocytes in Crohn’s disease. Arch Med Sci 2015; 11: 1279-85.
Wang GC, He QY, Tong DK, et al. MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4. J Bone Oncol 2016; 5: 51-6.
Chen X, Chen XG, Hu X, et al. MiR-34a and miR-203 inhibit survivin expression to control cell proliferation and survival in human osteosarcoma cells. J Cancer 2016; 7: 1057-65.
Li RZ, Wang LM. Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma. World J Surg Oncol 2016; 14: 150.
Liu M, Xiusheng H, Xiao X, et al. Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells. Oncol Rep 2016; 36: 3371-8.
Hori D, Dunkerly-Eyring B, Nomura Y, et al. miR-181b regulates vascular stiffness age dependently in part by regulating TGF-beta signaling. PloS One 2017; 12: e0174108.
Zheng Y, Lv X, Wang X, et al. MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep 2016; 35: 683-90.
Tian F, Shen Y, Chen Z, et al. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene 2016; 591: 338-43.
An TH, He QW, Xia YP, et al. MiR-181b antagonizes atherosclerotic plaque vulnerability through modulating macrophage polarization by directly targeting Notch1. Mol Neurobiol 2016 (PMID:27722924).
Yu F, Zhou G, Li G, et al. Serum miR-181b is correlated with hepatitis B virus replication and disease progression in chronic hepatitis B patients. Dig Dis Sci 2015; 60: 2346-52.
Peng Z, Li J, Li Y, et al. Downregulation of miR-181b in mouse brain following ischemic stroke induces neuroprotection against ischemic injury through targeting heat shock protein A5 and ubiquitin carboxyl-terminal hydrolase isozyme L1. J Neurosci Res 2013; 91: 1349-62.
Tao T, Wang Y, Luo H, et al. Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. Eur J Cancer 2013; 49: 3055-63.
Wang J, Sai K, Chen FR, et al. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 2013; 72: 147-58.
Guo JX, Tao QS, Lou PR, et al. miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev 2012; 13: 2263-7.
de Yebenes VG, Belver L, Pisano DG, et al. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med 2008; 205: 2199-206.
Yang L, Wang YL, Liu S, et al. miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. FEBS Letters 2014; 588: 124-30.
Wang B, Li W, Guo K, et al. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 2012; 421: 4-8.
Wang X, Chen X, Meng Q, et al. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFbetaR1/Smad signaling pathway in NSCLC. Sci Rep 2015; 5: 17618.
Sun YC, Wang J, Guo CC, et al. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer 2014; 14: 611.
Li P, Lu X, Wang Y, et al. MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res 2010; 24: 436-43.
Lyu Z, Mao Z, Wang H, et al. MiR-181b targets Six2 and inhibits the proliferation of metanephric mesenchymal cells in vitro. Biochem Biophys Res Commun 2013; 440: 495-501.
Li H, Hui L, Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sinica 2012; 44: 269-77.
Wang XF, Shi ZM, Wang XR, et al. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol 2012; 138: 573-84.
Cittelly DM, Das PM, Salvo VA, et al. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 2010; 31: 2049-57.
Yang J, Cao Y, Sun J, et al. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol 2010; 27: 1114-8.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe